The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.75
Bid: 45.50
Ask: 46.00
Change: -2.55 (-5.28%)
Spread: 0.50 (1.099%)
Open: 50.50
High: 46.50
Low: 45.50
Prev. Close: 48.30
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys

Mon, 19th Jun 2023 07:53

(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight.

"With some US markets closed for the Juneteenth public holiday, today's European session is likely to be a quiet one, with a modestly negative open after US markets finished the end of a positive week, with their first daily decline in six days," CMC Markets analyst Michael Hewson commented.

The pound was on the front foot ahead of the Bank of England's interest rate decision on Thursday, with Threadneedle Street expected to enact a 25 basis point hike. There will be UK inflation data on Wednesday, ahead of the BoE decision.

There will also be interest rate decisions from the People's Bank of China on Tuesday, and the Swiss National Bank on Thursday.

Meanwhile, US Secretary of State Blinken met with his Chinese counterpart Qin Gang at the start of his two-day trip to Beijing, a visit aimed at rebuilding the cratering relationship between the world's two largest economies.

A series of meetings with high-ranking government representatives are planned before Blinken - the most senior US official to visit China in years - leaves on Monday. It remains unclear whether he will meet with Chinese leader Xi Jinping.

In early UK economic news, house prices fell marginally in June, according to Rightmove. In company news, AstraZeneca is said to be mulling a spin-off of its Chinese business. The UK competition watchdog said it is eyeing up Severn Trent's acquisition of a food waste anaerobic digestion plant operator.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 34.0 points, 0.4%, at 7,608.72

----------

Hang Seng: down 1.1% at 19,815.13

Nikkei 225: closed down 0.9% at 33,400.47

S&P/ASX 200: closed up 0.6% at 7,294.90

----------

DJIA: closed down 108.94 points, 0.3%, at 34,299.12

S&P 500: closed down 0.4% at 4,409.59

Nasdaq Composite: closed down 0.7% at 13,689.57

----------

EUR: up at USD1.0941 (USD1.0926)

GBP: up at USD1.2825 (USD1.2819)

USD: up at JPY141.63 (JPY141.59)

GOLD: down at USD1,955.50 per ounce (USD1,960.83)

OIL (Brent): down at USD75.45 a barrel (USD75.62)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

US Juneteenth holiday. Financial markets closed.

11:00 BST Ireland goods exports and imports

----------

UK MPs vote Monday on a damning report that found ex-prime minister Boris Johnson deliberately lied to parliament about lockdown-breaking parties, in what the government hopes will be the final chapter in the damaging "Partygate" scandal. The parliamentary vote is being held on Johnson's 59th birthday as the wounded former leader ponders his next move, with allies predicting a future return to the electoral fray. It also comes at a time of mounting political problems for Rishi Sunak's Conservative government, as stubbornly high inflation and constantly rising interest rates inflict economic pain on voters.

----------

UK house prices suffered a marginal fall this month, the first June decline since 2017, according to a Rightmove tracker. Average new seller asking prices fell by just GBP82 in June to GBP372,812 from GBP372,894. Prices had risen 1.8% in May from April. Though fractional, June's outturn was the first monthly drop in asking prices this year. It was the first June fall in house prices since 2017. The outlook for house prices is less-than-stellar too, Rightmove predicts. The property portal expects asking prices to fall in most months for the rest of the year, in line with season patterns. Rightmove still predicts UK house prices to decline by 2% over the whole of 2023. Mortgage rates have increased recently, though Rightmove noted buyer demand has not been hurt. Demand over the last two weeks was 6% higher than in pre-pandemic 2019.

----------

BROKER RATING CHANGES

----------

Redburn raises Entain to 'buy' from 'neutral'

----------

HSBC raises Fevertree Drinks to 'buy' - price target 1,600 pence

----------

Deutsche Bank cuts Asos price target to 485 (725) pence - 'hold'

----------

COMPANIES - FTSE 100

----------

AstraZeneca has drafted plans to separate its China business amid geopolitical tensions, the Financial Times reported. The company is aiming to shield itself from simmering tensions between China, the world's second-largest economy, and the West. The FT, citing people familiar with the matter, reported that the Cambridge, England-based pharmaceutical company began discussing the idea with bankers "several months ago". It is among a growing number of multinational companies now considering that option, the FT added. A move may ultimately not take place, the FT sources said, though a Shanghai listing is also possible. The Chinese market is an attractive one for pharma firms, as the nation has an ageing population and as the government there speeds up the regulatory process for innovative medicines.

----------

The UK Competition & Markets Authority said it was looking at Severn Trent's acquisition of Andigestion to see whether it would lessen competition in the UK market. Back in February, the water utility had announced its green power unit's acquisition of Andigestion, which operates two food waste anaerobic digestion plants in southwest England. It said it expected the purchase to add another 45 gigawatt hours per year to its energy generation. "To assist it with this assessment, the CMA invites comments on the transaction from any interested party," the regulator said.

----------

Coca-Cola HBC announced it will acquire Brown-Forman Finland, which owns the Finlandia vodka brand, from Brown-Forman's Dutch subsidiary. It will pay USD220 million, and expects the acquisition to complete in the second half. It is subject to regulatory approvals. "Having been associated with the distribution of Finlandia for 17 years in several markets, we are excited by this unique and regionally relevant opportunity that will support the acceleration of our on-premise business across more of our markets," said Chief Executive Zoran Bogdanovic.

----------

COMPANIES - FTSE 250

----------

IT services provider Kainos said its CEO of 22 years, Brendan Mooney, will finish his term in the role by the end of September, with Digital Services Director Russell Sloan replacing him. Mooney will remain "actively engaged" with the business until next June, to ensure an orderly transition. "Brendan and Russell have worked closely as colleagues for many years and today formalises the final stage of our four-year succession process," said Chair Tom Burnet.

----------

RHI Magnesita received a partial cash offer for 30% of its shares from Ignite Luxembourg Holdings, a company indirectly managed by Rhone Holdings VI. Rhone is now offering GBP28.50 per share for 29.9% of the company. In late May, Rhone made a tilt for a 20% stake in the Vienna-based supplier of refractory products, also at GBP28.50 per share. At that time, it had said it reserved the right to increase the offer size to up to 29.9%. RHI Magnesita had said in May that its board was "considering its response to the partial offer and a further announcement will be made in due course".

----------

OTHER COMPANIES

----------

Life sciences firm Avacta Group denied media reports of plans for an imminent fundraising. "The company regularly considers potential funding opportunities, both non-dilutive and dilutive, to ensure its business operations remain well financed and the best interests of its stakeholders are maintained," it explained. Avacta said whilst it "[maintains] a dialogue" with shareholders and current investors, "no fundraising is imminent". It had cash of GBP27 million on the balance sheet at the end of May, and expects "strong news flow" in the coming months across the company.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
Today 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Quilter PLCQ1 Results
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
Tuesday 30 April 
Avacta Group PLCFull Year Results
Card Factory PLCFull Year Results
Capital & Regional PLCFull Year Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCHalf Year Results
Fadel Partners IncFull Year Results
Glencore PLCTrading Statement
Hargreaves Lansdown PLC Trading Statement
Howden Joinery PLCTrading Statement
HSBC Holdings PLCQ1 Results
Kelso Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Phoenix Spree Deutschland LtdFull Year Results
RBG Holdings PLCFull Year Results
Rotork PLCTrading Statement
Safestore Holdings PLCHalf Year Results
Shield Therapeutics PLCFull Year Results
St James's Place PLCTrading Statement
Whitbread PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Apr 2024 17:51

TRADING UPDATES: First Tin updates Tellerhauser estimates

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.

Read more
21 Mar 2024 10:37

Avacta doses third patient in drug conjugate trial for tumour tissue

(Alliance News) - Avacta Group PLC on Thursday said it dosed the third patient in the first cohort of its phase 1a dose escalation study for its lead preCision drug AVA6000.

Read more
18 Mar 2024 14:31

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million.

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Feb 2024 12:18

Avacta increases placing size to GBP26 million thanks to strong demand

(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand."

Read more
29 Feb 2024 10:27

AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
29 Feb 2024 08:27

Avacta tumbles after raising £25.7m in heavily discounted placing

(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.

Read more
28 Feb 2024 20:31

TRADING UPDATES: Avacta plans fundraise to fund clinical development

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Jan 2024 11:18

Avacta appoints new head of research and development

(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.

Read more
19 Jan 2024 09:11

IN BRIEF: Avacta says new head of R&D Coughlin brings "deep expertise"

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy.

Read more
19 Dec 2023 10:24

Avacta appoints new chief business officer

(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.

Read more
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.